سعر ميفينكول 500 مجم لبوس شرجي 2026

Chloramphenicol 500 mg rectal suppository by Misr (Egypt). Pack count not verified on opened directories.

• Serious susceptible bacterial infections when less toxic antibacterials are ineffective or contraindicated; also historically used in selected enteric infections. Systemic use is restricted because of rare but fatal aplastic anaemia.Population: Adults and children (specialist use)WHO Collaborating Centre for Drug Statistics Methodology

• Bone-marrow suppression (dose-related reversible and rare irreversible aplastic anaemia), nausea, vomiting, diarrhoea, hypersensitivity rashes, optic neuritis with prolonged use.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology

• Hypersensitivity to chloramphenicol. Do not use in patients with known bone-marrow suppression or previous chloramphenicol-associated blood dyscrasia.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology

• WARNING: Rare irreversible aplastic anaemia and other serious blood dyscrasias have occurred after systemic chloramphenicol, sometimes after short courses. Monitor blood counts; discontinue if blood dyscrasia develops. Avoid prolonged or repeated courses.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology
• Gray baby syndrome risk in neonates and premature infants with immature hepatic glucuronidation — avoid or use only with specialist monitoring.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology

• Phenytoin, warfarin, sulphonylureas (CYP-metabolised drugs)MajorChloramphenicol can inhibit hepatic metabolism and increase plasma levels of phenytoin, warfarin and some oral antidiabetics — monitor closely.WHO Collaborating Centre for Drug Statistics Methodology

• Systemic chloramphenicol crosses the placenta; avoid in late pregnancy near term because of Gray baby syndrome risk in the newborn. Use only if no safer alternative and benefit outweighs risk.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology
• Chloramphenicol is excreted in breast milk; breastfeeding is generally not recommended during systemic therapy.General active-ingredient information · WHO Collaborating Centre for Drug Statistics Methodology

• Chloramphenicol: Binds the 50S ribosomal subunit and inhibits bacterial protein synthesis (bacteriostatic).